Viking Upsizes Concurrent Offering to $500M; Common Priced at $35, Notes at 45% Premium
VKTX sits 54% above its 52-week low of $24.78 on elevated volume (5.2× avg).
Summary
Viking Therapeutics upsized its concurrent offering to $500 million, pricing 7.86 million common shares at $35.00 and $225 million of 2.00% convertible notes due 2032 with a 45% conversion premium.
Key Events · Financing and Capital Events · VKTX
-
Concurrent Offering Upsized to $500M
Common stock tranche increased from $200M to $275,000,005 (or $316.25M with full underwriter option); convertible notes tranche increased from $200M to $225M (or $258.75M with full over-allotment).
-
Common Stock Priced at $35.00
7,857,143 shares priced at $35.00 per share, a 16% discount to the $41.65 last reported sale price on September 23, 2026. Underwriting discount of $2.10 per share (6%).
-
Convertible Notes Terms Finalized
$225M of 2.00% convertible senior notes due 2032, with a 45% conversion premium (initial conversion price ~$50.75) and initial conversion rate of 19.7044 shares per $1,000 principal.
-
Combined Net Proceeds ~$476M
Approximately $258.2M from common stock and $218.0M from notes, after underwriting discounts and estimated expenses. Proceeds fund VK2735 and VK3019 clinical development plus general corporate purposes.
Analysis · VKTX · Life Sciences
Viking Therapeutics finalized pricing on its concurrent capital raise, upsizing the combined deal from $400 million to $500 million. The common stock tranche grew from $200 million to $275 million, priced at $35.00 per share — a 16% discount to the $41.65 last reported sale price on September 23, 2026. The convertible notes tranche grew from $200 million to $225 million, carrying a 2.00% coupon and a 45% conversion premium (initial conversion price ~$50.75). Combined net proceeds of roughly $476 million fund the VK2735 obesity program and VK3019 development. The discount on common stock reflects standard follow-on pricing mechanics, while the 45% conversion premium on the notes signals underwriter confidence in the equity story. Existing shareholders absorb dilution from 7.86 million new shares (9.04 million with the option), but the raise removes near-term financing risk for a company burning over $100 million per quarter.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $38.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $24.78 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.